Recently, Bria et al. showed a relevant relationship between the heterogeneity of EGFR mutations in NSCLC and duration of clinical response after TKI treatment: patients with a high proportion of EGFR mutated alleles responded better to TKIs [26]. Here, EGFR is linked to non-small cell lung carcinoma.